WallStreetZenWallStreetZen

NASDAQ: UNCY
Unicycive Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for UNCY

Based on 3 analysts offering 12 month price targets for Unicycive Therapeutics Inc

Min Forecast
$3.00+360.12%
Avg Forecast
$5.50+743.56%
Max Forecast
$7.50+1,050.31%

Should I buy or sell UNCY stock?

Based on 3 analysts offering ratings for Unicycive Therapeutics Inc.

Strong Buy
Strong Buy
1 analysts 33.33%
Buy
2 analysts 66.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although UNCY's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates UNCY as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +7.53% per year. Learn More

Be the first to know when Wall Street analysts revise their UNCY stock forecasts and price targets.

UNCY stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-21
lockedlocked$00.00+00.00%2025-04-11
lockedlocked$00.00+00.00%2024-11-22

1 of 1

Forecast return on equity

Is UNCY forecast to generate an efficient return?

Company
1,812.25%
Industry
142.9%
Market
80.27%
UNCY's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is UNCY forecast to generate an efficient return on assets?

Company
425.25%
Industry
35.65%
UNCY is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

UNCY earnings per share forecast

What is UNCY's earnings per share in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
-$0.04
Avg 2 year Forecast
$1.36
Avg 3 year Forecast
$2.83

UNCY revenue forecast

What is UNCY's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$14.8M
Avg 2 year Forecast
$424.0M
Avg 3 year Forecast
$851.2M

UNCY vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
UNCY$0.65$5.50+743.56%Strong Buy
CNTX$0.87$6.00+592.04%Strong Buy
AVTE$2.68N/AN/A
ELTX$4.92$10.00+103.25%Buy
CRVO$9.06$20.33+124.43%Strong Buy
View Top Biotech Stocks

Unicycive Therapeutics Stock Forecast FAQ

Is Unicycive Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: UNCY) stock is to Strong Buy UNCY stock.

Out of 3 analysts, 1 (33.33%) are recommending UNCY as a Strong Buy, 2 (66.67%) are recommending UNCY as a Buy, 0 (0%) are recommending UNCY as a Hold, 0 (0%) are recommending UNCY as a Sell, and 0 (0%) are recommending UNCY as a Strong Sell.

If you're new to stock investing, here's how to buy Unicycive Therapeutics stock.

What is UNCY's earnings growth forecast for 2025-2027?

(NASDAQ: UNCY) Unicycive Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.96%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.59%.

Unicycive Therapeutics's earnings in 2025 is -$37,824,000.On average, 4 Wall Street analysts forecast UNCY's earnings for 2025 to be -$5,087,464, with the lowest UNCY earnings forecast at -$51,473,161, and the highest UNCY earnings forecast at $77,808,267. On average, 3 Wall Street analysts forecast UNCY's earnings for 2026 to be $162,798,835, with the lowest UNCY earnings forecast at $110,128,624, and the highest UNCY earnings forecast at $196,316,243.

In 2027, UNCY is forecast to generate $338,166,698 in earnings, with the lowest earnings forecast at $237,015,951 and the highest earnings forecast at $439,317,445.

What is UNCY's revenue growth forecast for 2025-2027?

(NASDAQ: UNCY) Unicycive Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.17%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.07%.

Unicycive Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast UNCY's revenue for 2025 to be $1,772,831,435, with the lowest UNCY revenue forecast at $34,714,458, and the highest UNCY revenue forecast at $4,788,201,040. On average, 3 Wall Street analysts forecast UNCY's revenue for 2026 to be $50,756,487,189, with the lowest UNCY revenue forecast at $20,875,359,484, and the highest UNCY revenue forecast at $71,823,015,600.

In 2027, UNCY is forecast to generate $101,896,868,397 in revenue, with the lowest revenue forecast at $48,528,417,540 and the highest revenue forecast at $136,272,201,598.

What is UNCY's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: UNCY) forecast ROA is 425.25%, which is higher than the forecast US Biotechnology industry average of 35.65%.

What is UNCY's Price Target?

According to 3 Wall Street analysts that have issued a 1 year UNCY price target, the average UNCY price target is $5.50, with the highest UNCY stock price forecast at $7.50 and the lowest UNCY stock price forecast at $3.00.

On average, Wall Street analysts predict that Unicycive Therapeutics's share price could reach $5.50 by Apr 21, 2026. The average Unicycive Therapeutics stock price prediction forecasts a potential upside of 743.56% from the current UNCY share price of $0.65.

What is UNCY's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: UNCY) Unicycive Therapeutics's current Earnings Per Share (EPS) is -$0.56. On average, analysts forecast that UNCY's EPS will be -$0.04 for 2025, with the lowest EPS forecast at -$0.43, and the highest EPS forecast at $0.65. On average, analysts forecast that UNCY's EPS will be $1.36 for 2026, with the lowest EPS forecast at $0.92, and the highest EPS forecast at $1.64. In 2027, UNCY's EPS is forecast to hit $2.83 (min: $1.98, max: $3.67).

What is UNCY's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: UNCY) forecast ROE is 1,812.25%, which is considered strong.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.